Stock Events

Stock Events

Celldex Therapeutics 

€28.63
21
-€0.29-1% Today

Statistics

Day High
28.73
Day Low
28.52
52W High
29.08
52W Low
16.4
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q4 2025
Next
Next
-1.03
-0.98
-0.92
-0.87
Expected EPS
-1.01802855897
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCE2.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb competes in the oncology and immunology sectors, similar to Celldex's focus on cancer and immune-related diseases.
Merck
MRK
Mkt Cap277.02B
Merck is a leading company in cancer treatment with its blockbuster drug Keytruda, directly competing with Celldex's cancer therapies.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong presence in the oncology and immunology markets, areas where Celldex is actively developing treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on innovative therapeutics in oncology and other areas, overlapping with Celldex's therapeutic development programs.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is involved in developing monoclonal antibodies for cancer and inflammatory diseases, competing with Celldex's pipeline.
Incyte
INCY
Mkt Cap19.36B
Incyte operates in the oncology sector, particularly in developing therapies for cancer, which competes with Celldex's focus areas.
Exelixis
EXEL
Mkt Cap11.1B
Exelixis is focused on the discovery, development, and commercialization of new medicines for cancer treatment, directly competing with Celldex.
Novartis
NVS
Mkt Cap279.67B
Novartis is a global healthcare company that has a strong focus on innovative medicines in oncology, competing with Celldex's cancer therapies.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad portfolio including oncology, competing in the same therapeutic areas as Celldex, especially in cancer treatment.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a significant presence in oncology, with a pipeline that includes treatments for various cancers, competing with Celldex's offerings.

About

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Show more...
CEO
Mr. Anthony S. Marucci M.B.A.
Employees
198
Country
United States
ISIN
US15117B2025

Listings

MU
DE
TCE2.MU
STU
DE
TCE2.STU
F
DE
TCE2.F
BOATS
BOATS
CLDX.BOATS

0 Comments

Share your thoughts

FAQ

What is Celldex Therapeutics stock price today?▼
The current price of TCE2.STU is €28.63 EUR — it has decreased by -1% in the past 24 hours. Watch Celldex Therapeutics stock price performance more closely on the chart.
What is Celldex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Celldex Therapeutics stocks are traded under the ticker TCE2.STU.
Is Celldex Therapeutics stock price growing?▼
TCE2.STU stock has risen by +4.07% compared to the previous week, the month change is a +15.4% rise, over the last year Celldex Therapeutics has showed a +61.69% increase.
When is the next Celldex Therapeutics earnings date?▼
Celldex Therapeutics is going to release the next earnings report on August 06, 2026.
How many employees does Celldex Therapeutics have?▼
As of May 06, 2026, the company has 198 employees.
In which sector is Celldex Therapeutics located?▼
Celldex Therapeutics operates in the Health & Wellness sector.
When did Celldex Therapeutics complete a stock split?▼
Celldex Therapeutics has not had any recent stock splits.
Where is Celldex Therapeutics headquartered?▼
Celldex Therapeutics is headquartered in Hampton, United States.